Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) announced compelling real-world data demonstrating significant benefits of its RECELL® System in burn treatment. The analysis from the U.S. national burn registry showed that RECELL reduces hospital length of stay by 36% compared to traditional skin grafts in adults with deep second-degree burns.
The study of 741 adults revealed RECELL-treated patients experienced an average 5.6-day reduction in hospital stay, potentially saving over $42,000 per patient in costs. The system enables hospitals to treat 13 more patients per bed annually. RECELL requires 97.5% less skin compared to traditional grafts while improving donor site healing, pain, and scarring.
AI-generated analysis. Not financial advice.
Positive
- 36% reduction in hospital length of stay compared to traditional treatment
- Cost savings exceeding $42,000 per patient
- Increased hospital efficiency with capacity for 13 more patients per bed annually
- 97.5% less skin required compared to traditional grafts
- Higher proportion of patients discharged directly home
Negative
- None.
Insights
RECELL system shows remarkable 36% shorter hospital stays, $42,000 savings per patient, and increased hospital efficiency in burn treatment.
The real-world data from the U.S. national burn registry demonstrates compelling economic benefits for AVITA Medical's RECELL System. The 36% reduction in hospital length of stay (LOS) translates to approximately
This analysis involved a matched cohort of 741 adult patients, with 247 receiving RECELL treatment and 494 receiving traditional split-thickness skin grafts. The 5.6-day reduction in hospitalization is statistically significant (p < 0.0001) and represents meaningful clinical improvement.
Beyond direct cost savings, the operational efficiency gains are noteworthy. Hospitals could potentially treat 13 additional patients annually per bed using RECELL versus traditional methods. This throughput improvement is particularly valuable given that U.S. burn cases consumed over 110,000 ICU days in 2023, costing more than
The clinical advantages of RECELL requiring
From a clinical perspective, these findings represent a significant advancement in burn care. The 36% reduction in hospital stay isn't just an economic metric—it signifies substantially faster healing and recovery for patients with deep partial thickness burns.
The registry data is particularly valuable because it reflects real-world outcomes rather than controlled trial conditions. The matched analysis methodology (247 RECELL patients vs. 494 STSG patients) strengthens the validity of these findings by controlling for potential confounding variables.
Most telling is the higher proportion of RECELL-treated patients discharged directly home, indicating better overall recovery trajectories. This suggests patients experience improved functional outcomes that enable them to bypass extended rehabilitation settings.
The technical advantages of RECELL—creating an autologous skin cell suspension requiring
For a burn unit managing multiple patients with varying burn severities, these benefits compound. Reduced length of stay means decreased risk of hospital-acquired complications, lower pain medication requirements, earlier mobilization, and potentially better long-term psychological outcomes for patients—all critical factors in comprehensive burn care that go beyond the economic advantages.
- Analysis of U.S. national burn registry data demonstrates
36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin grafting - More than
$42,000 per patient cost savings, together with improved patient throughput, support operational and economic value
- Presented at the 2025 European Burn Association Congress in Berlin, Germany
VALENCIA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today reaffirmed real-world data from the U.S. national burn registry demonstrating that the use of the RECELL® System significantly reduces hospital length of stay (LOS) by an average of
Victoria Miles, EMTP, MD, of Louisiana State University Health and Sciences Center, presented the results of this research today at the 2025 European Burn Association Congress in Berlin, Germany: “These findings support the role of RECELL as a clinically validated, cost-effective option in modern burn management, and highlight the impact on patient outcomes, hospital efficiency, and resource utilization.”
RECELL harnesses the regenerative properties of a patient’s own skin to create an autologous skin cell suspension autograft, enabling clinicians to deliver a transformative solution at the point of care. In a matched analysis of 741 adults from the Burn Care Quality Platform registry, patients treated with RECELL (n=247) experienced an average 5.6-day reduction in hospital LOS, a
The reduction in LOS achieved upon the use of RECELL is not only clinically meaningful but also economically impactful. Based on an estimated average daily inpatient bed cost of
Amid a growing need to reduce the burden of burn care on hospital systems, the study’s findings are particularly compelling. In 2023 alone, U.S. burn cases consumed more than 110,000 ICU days, costing in excess of US
“The results from this real-world analysis underscore the transformative potential of RECELL in reducing hospitalization time and improving care efficiency,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “When you consider use of RECELL in deep-partial thickness burns requires
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Sources:
- Holmes Iv JH, Molnar JA, Carter JE, Hwang J, Cairns BA, King BT, Smith DJ, Cruse CW, Foster KN, Peck MD, Sood R, Feldman MJ, Jordan MH, Mozingo DW, Greenhalgh DG, Palmieri TL, Griswold JA, Dissanaike S, Hickerson WL. A Comparative Study of the ReCell® Device and Autologous Spit-Thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries. J Burn Care Res. 2018 Aug 17;39(5):694-702. doi: 10.1093/jbcr/iry029. PMID: 29800234; PMCID: PMC6097595.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “potential,” “project,” “target,” “will,” “would,” and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: industry market conditions; failure to obtain and/or maintain regulatory approvals and comply with applicable regulations; the conduct or outcome of pre-clinical or clinical (human) studies; market reaction to growth or product initiatives; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. Any forward-looking statements made herein are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
